NCT06370065View on ClinicalTrials.gov

Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 27, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2024

Conditions
Advanced Hepatocellular Carcinoma
Interventions
DRUG

HAIC+Serplulimab（HLX10）+ Bevacizumab Biosimilar（HLX04）

PD-1 inhibitor

Trial Locations (1)

Unknown

RECRUITING

Tianjin Cancer Hospital Airport Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER